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INTRODUCTION 
Current knowledge regarding the origin of micro- 
bodies, their function in cell metabolism, the man- 
ner in which they are destroyed or disposed of by 
the cell, and their responses to pathological  condi- 
tions  is  limited,  but  emerging  information  con- 
cerning  their  chemical  composition  (1,  2),  the 
structure  and  content  of their  nucleoid  (1,  3-5), 
and  their  possible  relationship  to  other  cell  or- 
ganelles  (6,  7)  provides  a  stimulating  and  useful 
background  for further  investigation. 
Though  a  limited  range  of  alteration  in  the 
number  or structure of microbodies  has  been  de- 
scribed,  these  organelles,  compared  to  other  cell 
constituents,  appear  relatively indolent and  unre- 
sponsive  to  most  experimental  manipulations. 
Accordingly,  new  information  relating  their 
morphologic and biochemical responses to specific 
metabolic  stimuli  may  prove  useful  for  further 
studies. 
Current  experiments  in  our  laboratories  have 
revealed  conspicuous  numerical  and  ultrastruc- 
rural changes in microbodies following administra- 
tion of a  hypolipidemic  agent  (ethyl  chlorophen- 
oxyisobutyrate,  CPIB)  capable of lowering serum 
lipid levels in man (8, 9) and in experimental ani- 
mals  (10).  The observations,  though preliminary, 
provide strong support for the proposal of Novikoff 
and  Shin (7)  that microbodies are related to lipid 
metabolism because the structural changes are ac- 
companied  by a  decrease  in  liver cholesterol and 
triglyceride  levels,  and  an  increase  in  liver cata- 
lase  activity and  weight.  Concomitantly,  a  slight 
increase  in liver protein  and  phospholipid  occurs 
(11,  12). 
Two electron microscope studies of rat liver fol- 
lowing CPIB treatment have been reported.  Paget 
(13)  described  an  increase in  size and  number  of 
mitochondria  and  the  formation  of  "giant  lyso- 
somes"  of uncertain  identity.  The  second  report 
(14)  related  the  effects  of  CPIB  treatment  to 
numerical changes in microbodies and  to enzyme 
activity in rat liver, but  neither alterations of the 
matrix  nor  other  changes  in  fine  structure  of 
microbodies  were  described. 
MATERIAL  AND  METHODS 
Eight male  CFE and  F-344 rats,  weighing approxi- 
mately  120 grams, were given 0.25  to 0.5% CPIB in 
chow diet and sacrificed at 3,  14,  and  30 days. Male 
C3H and Swiss Webster mice were treated similarly. 
The  animals  were  opened  under  light  ether  anes- 
thesia.  Small portions of liver were removed, minced 
into  blocks  of  1 mm  3 or  less,  fixed for  1 hr  in  2% 
osmium  tetroxide  buffered  with  s-collidine,  dehy- 
drated in alcohol, and embedded in epoxy resin. Thin 
sections were cut on an LKB 8800A ultramicrotome 
equipped with a DuPont diamond knife, stained with 
lead  (15),  and  examined with  an  RCA  3G electron 
microscope employing a 35 to 40/z objective aperture 
and an accelerating voltage of 50 kv. In all, approxi- 
mately  40  blocks  of tissue  were  examined  for  each 
time interval,  and  30 to 60 sections from each block 
were  studied.  Catalase  activity was  determined  by 
the  spectrophotometric  method  described  by  LOck 
(16).  Uricase  activity was  assayed  according  to  the 
procedure of Loudon and Hudson (17). 
RESULTS  ,,  • 
A  marked and  umf.0rm increase in the number of 
microbodies in:al! hepatocytes  (Fig.  l) and  a  pro- 
liferation  of the  smooth  endoplasmic  reticulum 
were the first alterations present as early as 3 days 
after  treatment  and  persisting  at  14  and  30  days. 
While many microbodies were of normal  size and 
had  typical  nucleoids,  others  were  identified  by 
their  density,  matrix  striations,  or  their  circular, 
single  membrane-limited  configuration.  Many 
microbodies  lacking  characteristic  nucleoids with 
a  crystalline substructure  had  a  flocculent matrix 
(Figs.  2  and  5).  Such  flocculent  structures  fre- 
quently possessed small matrix densities resembling 
immature or noncrystalline nucleoids and were at- 
tached  to  membranes  of the  endoplasmic  reticu- 
lure (Figs.  5, 6,  8,  9, and  11).  By 3 days, changes 
were  also  present  in  mitochondria.  Many  mito- 
chondria  had  membrane-limited  inclusions  con- 
taining wavy or beaded fibrils (Fig. 3) ; others were 
elongated  and  flattened,  with  close  apposition  of 
their limiting membranes  (Fig.  4). 
By  30  days  of  treatment,  many  microbodies 
were  bizarre  in  shape  and  size and  contained  in 
their matrix several linear "striations" or lamellae 
4~2  BRIEF  NOTES All figures are of sections of rat liver stained with lead. 
Ft(]u~E  1  After 3  days of CPIB  treatment. Marked increase in number and variation in size  of micro- 
bodies were  apparent.  While some microbodies had  nucleoids  (rob1),  most did  not  (mb~).  The  nucleoid, 
when present, was  usually small,  eccentric,  and  lacked  the  normal  erystalloid  substructure.  Intramito- 
chm~drial bodies containing fibrils are apparent at the unmarked arrows. X  17,000. approximately 500 to 600 A apart and 200 to 300 A 
wide  (Figs.  6  to  8,  and  10).  At this time interval 
also, several densities were  present  within cisterns 
of the endoplasmic reticulum.  Such densities were 
identifiable as microbodies or as material of similar 
structure, even in the absence of a  nucleoid, by the 
presence  of the  matrix  striations  (Figs.  7  and  8). 
Connections of newly formed atypical microbodies 
with membranes of the smooth endoplasmic reticu- 
lum  remained  prominent.  At  this  time  interval, 
catalase  activity  values  in  homogenates  were 
significantly higher than control values, while uri- 
case  levels were  unchanged or  slightly decreased. 
By 9  to  11  days,  there was a  similar increase in 
number of microbodies in the mouse,  but the in- 
crease was not uniform from cell to cell and matrix 
striations were not present. 
While many microbodies had diameters within 
the normal range of 0.3 to 0.6 #, there was an ob- 
vious increase in the proportion of these organelles 
that  had  a  diameter  at  the  smaller  end  of  the 
range, 0.2 to 0.3 #.  In contrast, those microbodies 
with  a  f[occulent  rather  than  compact  matrix 
usually had a diameter greater than 0.6 #. 
Many  microbodies  possessed  elongated,  strap- 
shaped  extensions  (Fig.  10)  that measured  0.7  to 
1#. 
DISCUSSION 
The  main  effects  of  CPIB  treatment  are  hypo- 
cholesterolemia and hepatomegaly (12). The cause 
of  hepatomegaly  is  unclear  at  present,  but  it  is 
evidently not related to the hypolipidemic effect of 
the  drug  because,  in  some  species,  decrease  in 
serum cholesterol occurs in the absence of hepato- 
megaly (18). Similarly, hepatomegaly is not due to 
increase in the number of microbodies since by  2 
wk  after withdrawal of CPIB  the liver weight re- 
turns  to  normal  but  the  increased  number  of 
microbodies persists (14). 
The  observation  that  microbodies  increase  re- 
markably  in  number  and  undergo  prominent 
changes  in  ultrastructure  simultaneously  with 
hypolipidemia  due  to  CPIB  treatment  suggests  a 
relationship,  although  indirect,  between  micro- 
bodies and lipid metabolism.  Striations or formed 
elements  similar  to  those  related  to  CPIB  treat- 
ment were  noted  by  Hruban  and  Swift  (5)  after 
administration of acetylsalicylic acid,  tetracycline, 
azaserine,  and thioacetamide.  While we have ob- 
served that microbodies show an increase in num- 
ber  and  a  variability in  size  after  thioacetamide 
treatment, we have not detected  matrix striations 
within  them.  With  another  hepatocarcinogen, 
N, N'-2 : 7-fluorenylenebisacetamide, however,  ex- 
tensive  clusters  of  microbodies  with  bleblike 
evaginations  of  their  limiting  membrane  were 
conspicuous (19)  (Fig.  12). 
Differences in the number of microbodies within 
zones  of hepatic  lobules  and  their  increase  after 
partial  hepatectomy  were  noted  by Novikoff and 
Shin  (7).  Continuity  of the  single limiting mem- 
brane  of  microbodies  to  smooth  endoplasmic 
reticulum  was  demonstrated  in  rat  livers  after 
partial  hepatectomy  and  dimethylaminoazoben- 
zene  administration  (7),  in  rat  hepatomas  (20), 
FIGURE ~  After 3 days of CPIB treatment. The matrix of the microbodies was of vari- 
able density and remained so at 14 and 30 days. The microbody on the right is of normal 
density and has a  small, eccentric nucleoid. Those in the center and on the left have a 
flocculent, less dense matrix. ×  ~9,000. 
FIGURE 3  A mitochondrion after 3 days of CPIB treatment. A membrane-limited area 
containing wavy or beaded fibrils, similar to those found in protein-deficient rat liver (30) 
and corpus striatum of the rat (31),  is apparent at the arrow.  X  66,000. 
FIGURE 4  Several mitochondria, after 3  days of  CPIB  treatment, were elongated and 
flattened, with close apposition of their limiting membranes. X  17,000. 
FIGURE 5  After  14  days  CPIB  treatment,  the  nmnber  of  microbodies  remained  in- 
creased. Those ~dth a flocculent matrix could be identified as microbodies because of their 
possession of a  nucleoid (rob1). Continuity of the limiting membrane with smooth endo- 
plasmic reticulum was frequently seen (arrow).)<  9600. 
444  B  1~  I  E  F  N  O  T  E  S BRIEF  NOTES  445 after thienylalanine  (21),  and  in normal liver (1). 
Dalton  (22),  in  a  study  of hepatomas,  concluded 
that  the  size  and  complexity of microbodies  was 
inversely  proportional  to  the  growth  rate  of the 
tumors.  He described tubules of 100  m# diameter 
in the matrix of microbodies.  In our studies cross- 
sections  of  microbodies  did  not  disclose  tubular 
structures;  instead, the formed elements were con- 
sistently  lamellar. 
Presumably,  the  increased  number  of  micro- 
bodies that  are  smaller  than  normal  represents  a 
true proliferation because the increase was present 
in all zones of the hepatic lobule and was accom- 
panied  by a  simultaneous  increase in catalase  ac- 
tivity in liver homogenates  (18,  23). 
Recent studies have suggested that the nucleoid 
of microbodies  in  several  species contains  uricase 
(1, 4),  and Afzelius (3)  has pointed out that  those 
species whose microbodies lack nucleoids also lack 
uricase.  While  the  relationship  appears  generally 
true, it is apparent that the presence of nucleoids is 
not an all-or-none phenomenon in a  single species 
(Fig.  1).  Though,  in  the  rat,  nucleoids  are  uni- 
formly present  in microbodies under  normal con- 
ditions,  our  studies  demonstrate  that,  after  CPIB 
treatment,  many  newly  formed  microbodies  lack 
nucleoids.  Accordingly,  under  the present experi- 
mental  conditions,  a  mixed  population  of micro- 
bodies exists in this species. While it might be ar- 
gued that the absence of a  nucleoid in most micro- 
bodies is a  result of a  plane of section failing to in- 
clude the nucleoid, numerical studies of normal rat 
liver indicate  that  a  central  section  through  the 
hepatic cell contains an average of 10 microbodies 
(range,  3 to  18),  with 6  (range, 2 to  11)  possessing 
a  nucleoid.  The  ratio  of  microbodies  to  mito- 
chondria in a normal rat liver cell is approximately 
1:8  (1),  after  CPIB  treatment  the  number  of 
microbodies  per  cell  increases  tenfold,  but  the 
number  containing  nucleoids  is  not  proportion- 
ately  increased.  Considering  that  numerous  ran- 
dom sections in control and experimental animals 
were examined in this study, it would appear that 
the absence of a  nucleoid in a  high percentage  of 
microbodies  is not just  an  accident  of sectioning, 
but instead represents a proliferation of new micro- 
bodies  which,  for  reasons  not  yet  clarified,  lack 
nucleoids.  Indeed, uricase levels after CPIB treat- 
ment  may be  unchanged  or  slightly decreased  at 
an  interval  when  microbodies  lacking  a  nucleoid 
are  prominent  and  catalase  activity is  increased. 
It  would  appear,  therefore,  that  under  selected 
experimental  conditions  the  enzymic constituents 
and  their  usual  morphological  equivalents  may 
become dissociated. Studies to determine this point 
are currently  in progress. 
While  the  origin  of  microbodies  cannot  un- 
equivocally  be  answered  by  the  present  studies, 
Figs.  7 and 8  support Novikoff and  Shin's sugges- 
tion  that  electron-opaque  material  may  be  de- 
pomed  m  the  cavmes  of  dilated  smooth  endo- 
plasmic  reticulum  before  the  cavities  separate 
from  the  main  reticulum  (7).  Similarly,  Higashi 
and  Peters  (24,  25),  from biochemical data,  have 
suggested  that  catalase  is  first  synthesized  in  the 
endoplasmic  reticulum  and  later  transferred  to  a 
particulate  fraction. 
Since the increase  in number  of microbodies is 
temporally associated with elevated catalase levels, 
it appears  that  their formation is an expression of 
synthesis  of enzyme  protein  for  intracellular  use. 
Alternatively,  it  has  been  suggested  that  micro- 
FIGURE 6  After thirty days  of  CPIB  treatment,  the  mierobodies  frequently assumed 
abnormal shapes with elongated extensions.  Matrix striations were conspicuous.  Note the 
polyribosomes (p)  and the attachment  of a  microbody to a  vesicle of the smooth endo- 
plasmic reticulum  (arrow).  The inset at lower right  illustrates  a  mierobody  (CPIB,  30 
days)  with a  protrusion  (arrow)  and with matrix containing short,  crescentic striations. 
X  66,000. 
FIGVREs 7 and 8  After 80 days of CPIB treatment.  Cisterns of the smooth endoplasmic 
reticulum  contained  dense  material  with  striations  (arrows,  Fig.  7,  unmarked  arrow, 
Fig. 8). Though the transitional forms were considerably smaller than normal microbodies, 
the density and the striations were indistinguishable from those of the matrix of typical 
microbodies after CPIB, and suggested origin from the dense material in the cisternae. 
Attachment to smooth endoplasmic reticulum is present at arrow  (*).  Fig. 7,  X  66,000; 
Fig. 8,  X  7~,000. 
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tions in gluconeogenesis (26), in the destruction of 
cell  metabolites  (27),  or  in  protection  against 
random  oxidative  destruction  of cell constituents 
by hydrogen peroxide  (28).  That the microbodies 
represent a secretory granule for export outside the 
parent  cell,  similar  to  zymogen  granules  in  the 
pancreas  (5),  seems  unlikely  since  there  is  little 
cytochemical  or  morphological  evidence  to  sup- 
port this analogy. 
Crystalline  bovine  hepatic  catalase  (Caperase, 
Laboratorio  P.E.V.Y.A.,  Barcelona,  Spain)  ad- 
ministered  parenterally  to  humans  has  been  re- 
ported  (29)  to  lower  serum  cholesterol  and  uric 
acid  levels.  Possibly,  the  endogenous  increase  of 
liver catalase is associated with the hypolipidemic 
effects of CPIB and the administered catalase may 
produce  its effect by a  similar mechanism. 
The manner  in which microbodies are disposed 
of by the cell is not clear (6,  7).  Bruni and  Porter 
(6)  reported  that  microbodies fuse with lysosomes 
to form bodies with the structural features of both. 
No  evidence  for  such  fusion  or  transition  forms 
was evident in our experiments. 
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